Shionogi Lays Out R&D Goals Ahead of Crestor Challenges
This article was originally published in Scrip
Japan's Shionogi is looking to bolster its presence in core therapeutic areas, unveiling positive new data for a novel constipation therapy and a raft of anti-infective projects at a recent R&D update.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.